A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Moderna, Inc. stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 58,339 shares of MRNA stock, worth $3.12 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
58,339
Previous 8,551 582.25%
Holding current value
$3.12 Million
Previous $911,000 660.48%
% of portfolio
0.11%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$101.21 - $166.61 $5.04 Million - $8.3 Million
49,788 Added 582.25%
58,339 $6.93 Million
Q1 2024

May 03, 2024

SELL
$85.37 - $115.44 $4.86 Million - $6.58 Million
-56,986 Reduced 86.95%
8,551 $911,000
Q4 2023

Feb 09, 2024

BUY
$69.51 - $104.43 $3.97 Million - $5.97 Million
57,144 Added 680.85%
65,537 $6.52 Million
Q3 2023

Nov 13, 2023

SELL
$96.41 - $126.61 $196,290 - $257,777
-2,036 Reduced 19.52%
8,393 $867,000
Q2 2023

Aug 03, 2023

SELL
$118.5 - $160.53 $2.54 Million - $3.45 Million
-21,474 Reduced 67.31%
10,429 $1.27 Million
Q1 2023

May 12, 2023

BUY
$135.66 - $197.02 $3.21 Million - $4.66 Million
23,665 Added 287.27%
31,903 $4.9 Million
Q4 2022

Feb 13, 2023

BUY
$118.38 - $210.04 $305,302 - $541,693
2,579 Added 45.57%
8,238 $1.48 Million
Q3 2022

Nov 07, 2022

SELL
$118.07 - $194.18 $208,629 - $343,116
-1,767 Reduced 23.79%
5,659 $669,000
Q2 2022

Aug 12, 2022

BUY
$117.13 - $176.59 $560,701 - $845,336
4,787 Added 181.39%
7,426 $1.06 Million
Q1 2022

May 11, 2022

BUY
$126.46 - $235.05 $333,727 - $620,296
2,639 New
2,639 $455,000
Q4 2020

Feb 12, 2021

SELL
$65.74 - $169.86 $31,226 - $80,683
-475 Closed
0 $0
Q3 2020

Nov 09, 2020

BUY
$54.34 - $94.85 $25,811 - $45,053
475 New
475 $34,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $20.9B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Bi Asset Management Fondsmaeglerselskab A Portfolio

Follow Bi Asset Management Fondsmaeglerselskab A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.